Vaxcyte Inc (PCVX) Hedge Fund & Institutional Holdings (Q2 2026)

PCVX ranks #1864 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

PCVX is a top-conviction position for Pivotal bioVenture Partners Investment Advisor LLC — at 26.9% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in PCVX belongs to FMR LLC, but the position matters far more to Pivotal bioVenture Partners Investment Advisor LLC, who has 26.9% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Fidelity has added to its PCVX position for two straight quarters, increasing it by $573.9M to reach $1.2B today.

David Shaw has trimmed its PCVX position for two straight quarters, cutting it by $57.0M while still holding $110.6M.

PCVX is up 0.1% today, and institutions have been net buyers of $1.2B this quarter — today's price move and the underlying institutional flow are pointing the same direction.

PCVX reported a net loss of $766.6M in its latest fiscal year.

• Not yet profitable — net loss of $766.6M in the latest fiscal year
• Net income declined year over year, from -$463.9M to -$766.6M
• Operating cash flow was negative, using $655.6M in cash
• Current ratio of 7.91x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.12x equity — within a conventional range